Tag Archives: FDAcopilot

Jeffrey Shuren, a key figure in the regulation of medical devices at the U.S. Food and Drug Administration (FDA), recently announced his decision to step down from his position, ending a tenure of 28 years at the agency. Shuren, who began his career at the FDA in 1998 within the Commissioner’s Office, later ascended to […]

Continue Reading

Over the past decade, significant strides have been made in the understanding and treatment of food allergies. This evolution was significantly highlighted through Dr. Kari Nadeau’s pioneering clinical trials at Stanford University with 85 food allergy patients, published by the New York Times 11 years ago. Dr. Nadeau’s work has paved the way for groundbreaking […]

Continue Reading

The Food and Drug Administration (FDA) uses the “breakthrough” designation to fast-track the development and review of drugs and devices aimed at treating severe conditions, with potential improvements over existing therapies. Despite similar development processes involving significant investment and clinical trials, breakthrough devices face a notably less predictable and longer path to reimbursement compared to […]

Continue Reading

Sun Life, an organization focused on employee and government benefits, has recently partnered with Hinge Health to enhance its musculoskeletal (MSK) care offerings through digital solutions. This collaboration will give Sun Life members specialized access to a range of Hinge Health’s services, including health coaching, orthopedic surgery consultations, physical therapy, and technology like surgery decision […]

Continue Reading

Embecta, a company known for manufacturing insulin syringes and pen needles, is reportedly exploring the possibility of a sale, according to a late report by the Financial Times. Established in Parsippany, New Jersey, Embecta was a division of BD until it became an independent entity in 2022. The company is also in the process of […]

Continue Reading

In the evolving landscape of clinical research, the prioritization of inclusion, innovation, and scalability has become essential for developing treatments that are not only safe and effective but also cater to diverse populations globally. Through leveraging advancements in data and technology, the industry is forging pathways toward more accessible, transformative, and efficient clinical trials. Inclusion […]

Continue Reading

Artiva Biotherapeutics, a biotech company specializing in innovative cell therapy, has successfully raised $167 million through its initial public offering (IPO), aimed at supporting the clinical trials for their novel treatment approaches for autoimmune diseases. Initially pricing the IPO at $12 per share, which fell below the expected price range of $14 to $16 per […]

Continue Reading

Recent developments in AI within the healthcare sector have shown considerable progress since 2021, featuring advancements in the use and commonality of technologies such as Chat GPT by OpenAI and generative AI. Hospitals are exploring AI applications in areas like medical coding, while health tech and medtech companies are broadening the scope of AI integrations […]

Continue Reading

Truvian Health, a company specializing in blood-testing technology, recently announced that it has raised $74 million in funding, securing partnerships with notable entities such as Shoppers Drug Mart, Canada’s largest pharmacy chain. The funding round was co-led by Great Point Ventures and Wittington Ventures, with additional contributions from existing investors like Medical Excellence Capital, Tao […]

Continue Reading

For patients suffering from gout, a painful form of arthritis caused by excess uric acid in the blood, conventional treatments may not always provide relief. In such cases, Amgen’s biologic drug has been a potential alternative, yet its effectiveness is often limited by the immune system which might recognize the therapeutic protein as foreign, initiating […]

Continue Reading